Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Elevance Health, Inc. filings on SEC EDGAR ↗
Elevance Health officers are meeting with investors and analysts to reaffirm the company's full-year 2026 financial guidance. The company continues to expect adjusted shareholders’ earnings of at least $29.00 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points.
Elevance Health EVP & Chief Digital Info Ofr Ratnakar Lavu Sells $572K of Stock
Ratnakar Lavu, EVP & Chief Digital Info Ofr, sold 1,300 shares of Elevance Health, Inc. at $440.00 a share, worth $572K in total on Nov 5, 2026. Shares held after the trade: 14,849 (-8.1%).
Elevance Health EVP & CFO Mark Kaye Sells $4.66M of Stock
Mark Kaye, EVP & CFO, sold 10,584 shares of Elevance Health, Inc. at $434.00 to $447.19 a share (average $440.13) in 13 transactions, worth $4.66M in total on Oct 22, 2026. Shares held after the trade: 19,919 (-1.4%).
For the nine months ended September 30, 2026, Elevance Health reported total operating revenue of $149.8 billion, a slight increase from $148.3 billion in the prior year period. However, shareholders' net income decreased to $4.59 billion compared to $5.12 billion in 2025, primarily driven by higher operating expenses and a decrease in net income for the nine-month period.
Elevance Health reported Q3 2026 operating revenue of $50.4 billion and raised its full-year 2026 adjusted diluted EPS guidance to at least $29.00. The results were driven by improved operating performance in Medicare Advantage and Individual ACA, alongside growth in CarelonRx product revenue.
Term
Q3 2026
“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.”
Gail K. Boudreaux, President and Chief Executive Officer